within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02A_AntiadrenergicAgentsCentrallyActing.C02AC05_Moxonidine;

model Moxonidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.88,
    Cl = 2.1666666666666665e-06,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.0018,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Moxonidine</td></tr><tr><td>ATC code:</td><td>C02AC05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>130</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Moxonidine is an antihypertensive agent, acting as an imidazoline receptor agonist, predominantly used to treat mild to moderate essential hypertension. It reduces sympathetic nervous system activity, leading to vasodilation and lowered blood pressure. Moxonidine is approved and in clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers, mostly men and women, aged 18-65, after single oral dose under fasting conditions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02AC05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Moxonidine;
